Biology subjects

Prasad, H.

Publications and source records attributed to Prasad, H..

7 recordsLinked to original sources

bioRxiv2026

Endosomal pH Triggers Amyloid β Oligomerization and Maladaptive Phenotypic Plasticity in Alzheimers Disease

Endosomal dysfunction is a presymptomatic hallmark of neurodegeneration. Recent evidence highlights dysregulation of endosomal pH as a central pathogenic hub in Alzheimer's disease (AD); however, the mechanisms linking pH shifts to neurodegeneration remain incompletely defined. Here, we use a quantitative model of endosomal acidification driven by proton pumping via the vacuolar ATPase, proton leak via the endosomal Na/H exchanger NHE6, and other ion-regulating elements. The model recapitulates how downregulation of NHE6 in AD promotes endosomal hyperacidification, potentially triggering maladaptive phenotypic plasticity, an initially adaptive response that becomes pathological. Analysis of human brain datasets reveals reciprocal enrichment of NHE6 in neurons and the related NHE9 in glia, with NHE6 co-expression networks enriched for synaptic signalling. Systematic curation of NHE6 patient variants indicates that loss-of-function is associated with late regression, consistent with progressive endosomal hyperacidification, supporting a conceptual framework where early compensation transitions to neurodegeneration. Mathematical analyses calibrated for neuronal endosomes reveal a saturable relationship between luminal pH and NHE6 dosage, with threshold-like behaviour below ~50% expression that hyperacidifies endosomes, correlating with AD severity. Our model suggests this pH shift may exponentially accelerate A{beta} oligomerization and enhance {beta}-secretase activity. Furthermore, A{beta} oligomerization estimates correlate with dysregulation of calcium signalling and synaptic dysfunction. Model findings are compared with experimental results from NHE6-null mice and a cell culture model of AD. Drawing parallels to cancer, we propose that endosomal pH serves as a conserved regulator of adaptive-to-maladaptive transitions. Restoring physiological endosomal pH may offer a therapeutic window to prevent irreversible neurodegeneration in AD.

neuroscience↗

bioRxiv2026

Predicting recovery trajectories and injury severity following partial crush spinal cord injury in mice

The partial crush spinal cord injury (SCI) model enables preclinical testing of experimental therapies in mice, but substantial inter-animal variability in recovery outcomes confounds efficacy assessments. Here, we used open field behavioral data collected during the first 3 days post partial thoracic SCI to generate an Acute Functional Score (AFS) that defined three subgroups with divergent recovery trajectories. Applying latent class growth analysis and growth mixture modeling to open field and grid walk testing data, we demonstrated 83-92% prediction accuracy for AFS-defined recovery trajectories. The three subgroups differed significantly in treadmill kinematics and histological assessments of lesion size and astrocyte bridging. Applying the recovery trajectory framework to mice receiving saline or biomaterial vehicle injections at 3 days post-SCI revealed robust predictive accuracy while exposing disproportionate injury severity distributions between experimental groups. The approach enables individualized post-SCI recovery characterization that can neutralize procedural bias, minimize animal numbers, and provide a probabilistic basis for evaluating whether interventions enhance or suppress wound repair processes. Our findings establish a foundation for improving preclinical SCI study design and accelerating identification of effective therapies.

neuroscience↗

bioRxiv2022

A novel maxillofacial technique to deliver drugs to the visual pathway, the optic nerve and the retina using the glymphatic system.

The blood neural barriers are formidable barriers that prevent delivery of drugs into the eye and the brain. Currently, large biologics are used for treating many diseases of the eye and the brain. But the blood retinal barrier and the blood brain barrier prevent entry of these useful drugs into the eye and the brain respectively. Hence, there is a need for a drug delivery technique to bypass these natural barriers. Bevacizumab (Avastin) is a full length humanized monoclonal antibody with a molecular weight of 149kda. It binds to circulating vascular endothelial growth factor A and prevents interaction with vascular endothelial growth receptors. This results in blocking endothelial response and tumor vascularization. Bevacizumab is used to prevent choroidal neovascularization in age related macular degeneration and to prevent retinal neovascularization in diabetic retinopathy. It is also used for treating certain types of brain cancer. But it crosses neither the blood retinal barrier nor the blood brain barrier. This in vivo mouse study assessed the delivery of a commercial formulation of bevacizumab into the retina of mice using different ocular techniques like topical drops, subconjunctival injection, intravitreal injection and a novel maxillofacial technique. The objective was to assess whether the novel maxillofacial drug delivery technique could deliver drugs into the retina and to compare the efficacy of the maxillofacial technique with the mentioned ocular techniques. The distribution of bevacizumab was further compared with retinoschisin which is a small protein with a molecular weight of 24kda. Intravitreal injection and maxillofacial technique were effective in delivering drugs into the retina. In addition, the maxillofacial technique could target the brain including regions involved in the visual pathway and the optic nerve. The glymphatic pathway could also be targeted for drug delivery. Drug was also detected in the contralateral optic nerve and retina. Based on our study findings, we propose a new concept to explain the presence of the drug in the contralateral eye. We propose that after maxillofacial drug delivery, early distribution of the drug can occur in the CSF at the optic chiasma from the brain via the glymphatic system. In the case of the intravitreal injection, the drug from the experimental eye may be cleared through the glymphatic pathway of the ipsilateral optic nerve into the CSF surrounding the nerve. The crossover of the ipsilateral optic nerve fibers at the optic chiasma can result in further distribution of the drug in the CSF at the optic chiasma. From the region of the optic chiasma, the drug can distribute into the CSF surrounding the contralateral optic nerve. The drug can be then distributed into the contralateral optic nerve through the glymphatic pathway and be delivered into the contralateral eye. The drug can be further cleared into the aqueous of the contralateral eye through the anterior clearance pathway.

neuroscience↗

bioRxiv2018

A Moonlighting Role for SPCA2 in E-cadherin Biogenesis and Suppression of Epithelial-Mesenchymal Transition

Progression of benign tumors to invasive, metastatic cancer requires loss of the cell-adhesion protein E-cadherin. Although intensive efforts have focused on gene repression and silencing mutations, much less is known about posttranslational control of E-cadherin expression in cancer. SPCA2 is a secretory pathway Ca2+-ATPase that is down-regulated in metastatic breast cancer. We show that SPCA2 is tightly co-expressed with epithelial signature genes and required for E-cadherin biogenesis and cell surface expression. Unexpectedly, this function is uncoupled from Ca2+ pumping and mediated by binding to E-cadherin. Loss of SPCA2 is sufficient to disrupt cell-cell adhesion in tumorspheres and elicit mesenchymal gene expression through Hippo-YAP signaling. These findings point to a causal link between low SPCA2 levels and the epithelial-mesenchymal transition required for breast cancer metastasis.\n\nHighlightsO_LISPCA2 is an epithelial marker transcriptionally linked to E-cadherin expression\nC_LIO_LILoss of SPCA2 impairs E-cadherin biogenesis independent of Ca2+ pump activity\nC_LIO_LISPCA2 is required for tumorsphere formation and Hippo-YAP signaling to antagonize epithelial-mesenchymal transition\nC_LIO_LIDown-regulation of SPCA2 in metastatic cancers may contribute to malignancy\nC_LI\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=168 SRC=\"FIGDIR/small/379586_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (28K):\norg.highwire.dtl.DTLVardef@6b1e14org.highwire.dtl.DTLVardef@83edbborg.highwire.dtl.DTLVardef@16cbc5corg.highwire.dtl.DTLVardef@1c2752a_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗

bioRxiv2018

NHA2 promotes cyst development in an in vitro model of polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2 encoding polycystin-1 (PC1) and polycystin-2 (PC2), respectively. The molecular pathways linking polycystins to cyst development in ADPKD are still unclear. Intracystic fluid secretion via ion transporters and channels plays a crucial role in cyst expansion in ADPKD. Unexpectedly, we observed significant and selective up-regulation of NHA2, a member of the SLC9B family of Na+/H+ exchangers that correlated with cyst size and disease severity in ADPKD patients. Using three-dimensional cultures of MDCK cells to model cystogenesis in vitro, we show that ectopic expression of NHA2 is causal to increased cyst size. Induction of PC1 in MDCK cells inhibited NHA2 expression with concordant inhibition of Ca2+ influx through store-dependent and independent pathways, whereas reciprocal activation of Ca2+ influx by a dominant negative, membrane-anchored C-terminal tail fragment of PC1 elevated NHA2. We show that NHA2 is a target of Ca2+/NFAT signaling and is transcriptionally induced by methylxanthine drugs such as caffeine and theophylline, which are contraindicated in ADPKD patients. Finally, we observe robust induction of NHA2 by vasopressin, which is physiologically consistent with increased levels of circulating vasopressin and up-regulation of vasopressin V2 receptors in ADPKD. Our findings have mechanistic implications on the emerging use of vasopressin V2 receptor antagonists such as tolvaptan as safe and effective therapy for PKD and reveal a potential new regulator of transepithelial salt and water transport in the kidney.

physiology↗

bioRxiv2018

A conserved mechanism for regulation of endo-lysosomal pH by histone deacetylases

The pH of the endo-lysosomal system is tightly regulated by a balance of proton pump and leak mechanisms that are critical for storage, recycling, turnover and signaling functions in the cell. Dysregulation of endo-lysosomal pH has been linked to aging, amyloidogenesis, synaptic dysfunction, and various neurodegenerative disorders including Alzheimers disease. Therefore, understanding mechanisms that regulate luminal pH may be key to identifying new targets for treatment of these disorders. Meta-analysis of yeast microarray databases revealed that nutrient limiting conditions upregulated transcription of the endosomal Na+/H+ exchanger Nhx1 by inhibition of the histone deacetylase (HDAC) Rpd3, resulting in vacuolar alkalinization. Consistent with these findings, Rpd3 inhibition by the HDAC inhibitor and antifungal drug trichostatin A induced Nhx1 expression and vacuolar alkalinization. Bioinformatics analysis of Drosophila and mouse databases revealed that caloric control of Nhx1 orthologs DmNHE3 and NHE6 respectively, was also mediated by histone deacetylases. We show that NHE6 is a target of cAMP-response element-binding (CREB) protein, providing a molecular mechanism for nutrient and HDAC dependent regulation of endosomal pH. Control of NHE6 expression by pharmacological targeting of the CREB pathway can be used to regulate endosomal pH and restore defective amyloid A{beta} clearance in an ApoE4 astrocyte model of Alzheimers disease. These observations from yeast, fly, mouse and cell culture models reveal an evolutionarily conserved mechanism for regulation of endosomal NHE expression by histone deacetylases and offer new therapeutic strategies for modulation of endo-lysosomal pH in fungal infection and human disease.

molecular biology↗

bioRxiv2018

The Amyloid Clearance Defect in ApoE4 Astrocytes is Corrected by Epigenetic Restoration of NHE6

The accumulation of amyloid protein A{beta} in senile plaques is a key driver and hallmark of Alzheimer disease (AD), a major cause of death and dementia in the elderly. The strongest genetic risk factor in sporadic AD is the {varepsilon}4 allele of Apolipoprotein E (ApoE4), which potentiates pre-symptomatic endosomal dysfunction and defective clearance of A{beta}, although how these two pathways are linked has been unclear. Here, we show that aberrant accumulation of endosomal protons in ApoE4 astrocytes traps the LRP1 receptor in non-productive intracellular compartments, leading to loss of surface expression and A{beta} clearance. Hyperacidification of endosomal pH is caused by selective down regulation of the Na+/H+ exchanger NHE6, which functions as a critical proton leak pathway, in ApoE4 brain and astrocytes. In vivo, the NHE6KO mouse model shows elevated A{beta} in the brain. Epigenetic restoration of NHE6 expression with histone deacetylase inhibitors normalized ApoE4-specific defects in endosomal pH, LRP1 trafficking and amyloid clearance. Thus, NHE6 is a prominent effector of ApoE4 and emerges as a promising therapeutic target in Alzheimer disease.

neuroscience↗